COMBATING NRAS MUTANT MELANOMA: FROM BENCH TO BEDSIDE.

Jeffrey Alan Sosman, Muaiad Kittaneh, Martijn PJK Lolkema, Michael Andrew Postow, Gary Schwartz, Catherine Franklin, Alessandro Matano, Suraj Bhansali, Sudha Parasuraman, Kevin Kim, None, A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity. Journal of Clinical Oncology. ,vol. 32, pp. 9009- 9009 ,(2014) , 10.1200/JCO.2014.32.15_SUPPL.9009

Sheng-Bin Peng, James R. Henry, Michael D. Kaufman, Wei-Ping Lu, Bryan D. Smith, Subha Vogeti, Thomas J. Rutkoski, Scott Wise, Lawrence Chun, Youyan Zhang, Robert D. Van Horn, Tinggui Yin, Xiaoyi Zhang, Vipin Yadav, Shih-Hsun Chen, Xueqian Gong, Xiwen Ma, Yue Webster, Sean Buchanan, Igor Mochalkin, Lysiane Huber, Lisa Kays, Gregory P. Donoho, Jennie Walgren, Denis McCann, Phenil Patel, Ilaria Conti, Gregory D. Plowman, James J. Starling, Daniel L. Flynn, Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers Cancer Cell. ,vol. 28, pp. 384- 398 ,(2015) , 10.1016/J.CCELL.2015.08.002

Ophir Shalem, Neville E. Sanjana, Ella Hartenian, Xi Shi, David A. Scott, Tarjei S. Mikkelsen, Dirk Heckl, Benjamin L. Ebert, David E. Root, John G. Doench, Feng Zhang, Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells Science. ,vol. 343, pp. 84- 87 ,(2014) , 10.1126/SCIENCE.1247005

Igor Puzanov, Jeffrey Sosman, Armando Santoro, Muhammad W. Saif, Laura Goff, Grace K. Dy, Paolo Zucali, Julie A. Means-Powell, Wen Wee Ma, Matteo Simonelli, Robert Martell, Feng Chai, Maria Lamar, Ronald E. Savage, Brian Schwartz, Alex A. Adjei, Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors Investigational New Drugs. ,vol. 33, pp. 159- 168 ,(2015) , 10.1007/S10637-014-0167-5

Deborah JL Wong, Lidia Robert, Mohammad S Atefi, Amanda Lassen, Geetha Avarappatt, Michael Cerniglia, Earl Avramis, Jennifer Tsoi, David Foulad, Thomas G Graeber, Begonya Comin-Anduix, Ahmed Samatar, Roger S Lo, Antoni Ribas, Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma Molecular Cancer. ,vol. 13, pp. 194- 194 ,(2014) , 10.1186/1476-4598-13-194

Gerald S Falchook, Karl D Lewis, Jeffrey R Infante, Michael S Gordon, Nicholas J Vogelzang, Douglas J DeMarini, Peng Sun, Christopher Moy, Stephen A Szabo, Lori T Roadcap, Vijay GR Peddareddigari, Peter F Lebowitz, Ngocdiep T Le, Howard A Burris, Wells A Messersmith, Peter J O'Dwyer, Kevin B Kim, Keith Flaherty, Johanna C Bendell, Rene Gonzalez, Razelle Kurzrock, Leslie A Fecher, Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncology. ,vol. 13, pp. 782- 789 ,(2012) , 10.1016/S1470-2045(12)70269-3

Panagis Filippakopoulos, Stefan Knapp, Targeting bromodomains: epigenetic readers of lysine acetylation Nature Reviews Drug Discovery. ,vol. 13, pp. 337- 356 ,(2014) , 10.1038/NRD4286

Douglas B. Johnson, Igor Puzanov, Treatment of NRAS-mutant melanoma Current Treatment Options in Oncology. ,vol. 16, pp. 15- 15 ,(2015) , 10.1007/S11864-015-0330-Z

John A. Jakob, Roland L. Bassett, Chaan S. Ng, Jonathan L. Curry, Richard W. Joseph, Gladys C. Alvarado, Michelle L. Rohlfs, Jessie Richard, Jeffrey E. Gershenwald, Kevin B. Kim, Alexander J. Lazar, Patrick Hwu, Michael A. Davies, NRAS mutation status is an independent prognostic factor in metastatic melanoma Cancer. ,vol. 118, pp. 4014- 4023 ,(2012) , 10.1002/CNCR.26724

Douglas B. Johnson, Christine M. Lovly, Marisa Flavin, Katherine S. Panageas, Gregory D. Ayers, Zhiguo Zhao, Wade T. Iams, Marta Colgan, Sarah DeNoble, Charles R. Terry, Elizabeth G. Berry, A. John Iafrate, Ryan J. Sullivan, Richard D. Carvajal, Jeffrey A. Sosman, Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer immunology research. ,vol. 3, pp. 288- 295 ,(2015) , 10.1158/2326-6066.CIR-14-0207